investigation of melatonin in sleep quality in patients with cancer

investigation of effectiveness and non effectiveness of melatonin in sleep quality in patients with

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016051027840N1

Enrollment

Registered

2016-06-30

Start date

2016-07-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sleep quality disorders. sleep disorders

Interventions

Intervention group will receive 3 mg of melatonin daily for 1 month.

Treatment - Drugs

Intervention group will receive 3 mg of melatonin daily for 1 month

Eligibility

Sex/Gender

All

Age

16 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 16 to 80; Cancer patients who have trouble sleeping and chemotherapy have done for them and ended Exclusion criteria: patients with underlying disorders and uncontrolled medical problems such as diabetes, hypertension, seizures; addiction and continuous use of sleep medications and anticoagulants and anticonvulsants; Individuals treated with anticoagulants and anticonvulsants and antidepressants and sleeping drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sleep quality. Timepoint: Baseline,once a week for a amonth. Method of measurement: Based on pittsburgh sleep quality questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Tanhaie

Kermanshah University of Medical Sciences

s.tanhaie@kums.ac.ir+98 83 3427 6300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026